Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

NVOPositive Net Change MRKPositive Net Change MRNANegative Net Change CTMXNegative Net Change

Zacks Equity Research

Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

MRKPositive Net Change MRNANegative Net Change SRPTNegative Net Change CTMXNegative Net Change